IL2 and neoplasm: Other strategies that enhance T cell function, such as IL-21 supplementation to promote effector T cell growth and activity, or Treg-targeted therapies like RG6292 to deplete Tregs without disrupting IL-2 signaling in effector T cells, show promise in restoring anti-tumor immune responses [91,92].